Skip to main content

Table 1 Patient, surgery and tumor characteristics, reported as n(%), or median[IQR]

From: RandomiSed clinical trial assessing Use of an anti-inflammatoRy aGent in attenUating peri-operatiVe inflAmmatioN in non-meTastatic colon cancer – the S.U.R.G.U.V.A.N.T. trial

  Total (n = 60) Saline (n = 28) Taurolidine (n = 32) p-value
Sex
 F 21 (35%) 6 (21.4%) 15 (46.9%) 0.07
 M 39 (65%) 22 (78.6%) 17 (53.1%)
Age 69 [59.8, 72.2] 67 [58.8, 72] 69.5 [65.2, 72.2] 0.49
Surgery
 Anterior resection 27 (45%) 12 (42.8%) 15 (55.6%) 0.55
 Right hemicolectomy 23 (38.3%) 12 (42.8%) 11 (40.7%)
 Total colectomy 1 (1.7%) 0(0%) 1 (3.7%)
 Other 9 (15%) 4 (14.2%) 5 (15.6%)
Procedure
 Converted 6 (10%) 3 (10.7%) 3 (9.4%) 0.59
 Lap 47 (78.3%) 23 (82.1%) 24 (75%)
 Open 7 (11.7%) 2 (7.1%) 5 (15.6%)
Primary tumor
 T1 4 (6.7%) 1 (3.6%) 3 (9.3%) 0.59
 T2 8 (13.3%) 5 (17.8%) 3 (9.3%)
 T3 34 (56.6%) 16 (57.1%) 18 (56.2%)
 T4 8 (13.3%) 2 (7.1%) 6 (18.8%)
 T4a 4 (6.7%) 3 (10.7%) 1 (3.2%)
 T4b 1 (1.7%) 1 (3.5%) 0 (0%)
 Carcinoid 1 (1.7%) 0 (0%) 1 (3.2%)
Regional lymph nodes
 N0 31 (51.6%) 12 (42.8%) 19 (59.4%) 0.37
 N1 9 (15%) 5 (17.8%) 4 (12.5%)
 N1a 7 (11.6%) 4 (14.2%) 3 (9.4%)
 N1b 6 (10.0%) 3 (10.8%) 3 (9.4%)
 N2 5 (8.4%) 3 (10.8%) 2 (6.2%)
 N2b 2 (3.4%) 1 (3.6%) 1 (3.1%)
Lymph node yield 17 16 18 0.58
Follow-up (months) 34 32 37 0.23